Safety and efficacy of S-1 plus oxaliplatin 130 mg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A)

KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC)

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Safety and efficacy of S-1 plus oxaliplatin 130 mg/m<sup>2</sup> combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A)'. Together they form a unique fingerprint.

Medicine & Life Sciences